Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

计划入组 75 人 · 首次发布于 2024 年 11 月 4 日

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

计划入组 110 人 · 首次发布于 2025 年 9 月 22 日

Complement C5 mAb in the Treatment of Anti-GBM Disease

计划入组 16 人 · 首次发布于 2024 年 7 月 22 日

Complement-C1 inhibitor protein (Octapharma)

Complement C1 inhibitor protein subcutaneous(Takeda)

Complement-C1 inhibitor protein(Octapharma AG)

Protein Sciences Corporation

United States

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Dianthus Therapeutics

United States

Astellas Withdraws European Application for Avacincaptad Pegol in Geographic Atrophy

Astellas Seeks First Japanese Approval for Geographic Atrophy Treatment with Avacincaptad Pegol

Newcastle Study Shows Safe Withdrawal of Eculizumab in Rare Kidney Disease, Saving NHS £4.2 Million Per Patient